Drugs / IIV4c
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04576702 Comparator | Oct 2020 → Mar 2021 | influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IIV4c | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04576702 ↗ |
| Known as | QIVc | “Eligible participants aged ≥50 years were randomised 1: 1:1:1 to receive aQIVc (n = 116), a non-adjuvanted quadrivalent cell-based influenza vaccine (QIVc; n = 119), an...” PMID 39946829 ↗ Feb 2025 |
| Modality | Vaccine | “Licensed, Non-adjuvanted, Cell-derived Quadrivalent Influenza Vaccine” NCT04576702 ↗ |
| Route | Intramuscular | “IIV4c will be administered as a single dose intramuscularly on Day 1” NCT04576702 ↗ |